"ASH: Diabetes risk slowed with angiotensin receptor blocker"
Source: Medical Post
Published: 21 Jun 2022
Category: Pharmaceutical
Rating:
(2½ stars)
what they said (Hover the mouse cursor over underlined words for more info)
Researchers took a closer look at the massive data from a major clinical trial and found that receiving the angiotensin receptor blocker valsartan helped prevent hypertensives from developing diabetes.
"These new results should help physicians as they select anti-hypertensive agents for their patients, especially for those at higher risk of developing diabetes," said Dr. Kenneth Jamerson, a professor of internal medicine at the University of Michigan in Ann Arbor.
"Since we know from other studies that other hypertension medications such as diuretics come with a higher risk of diabetes, this result is especially interesting."
The original article can be found at: http://www.medicalpost.com/mpcontent/article.jsp?content=20050619_194619_5408
The original article can found in the Media Doctor archives.
Criteria |
Rating |
Availability of Treatment |
Not Satisfactory (?) |
Novelty of Treatment |
Satisfactory (?) |
Disease Mongering |
Satisfactory (?) |
Treatment Options |
Not Satisfactory (?) |
Costs of Treatment |
Not Satisfactory (?) |
Evidence |
Satisfactory (?) |
Quantification of Benefits of Treatment |
Satisfactory (?) |
Harms of Treatment |
Not Satisfactory (?) |
Sources of Information |
Not Satisfactory (?) |
Relies on Press Release |
Not Applicable |
Quantification of Harms of Treatment |
Not Applicable |
what we said (Hover the mouse cursor over underlined words for more info)
This article's key strength may be in the discussion of the evidence. Though not discussed specifically, the size and general characteristics of the study are disclosed.
The evidence is reported in both absolute and relative frames, or the absolute frame only, and rates with and without treatment. This, however, is not balanced by a discussion of rates of harm. Nor does the article make any attempt at independent corroboration of the evidence.
public forum
There are currently no comments on this article.
|